LIXTE and its Collaborators Expand Clear Cell Ovarian Cancer Trial

Stock Information for Lixte Biotechnology Holdings Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Lixte Biotechnology Holdings Inc.

DE LA SOUL-LED "GOOD HEALTH SUMMIT" LAUNCHES FEBRUARY 19 AT MOREHOUSE COLLEGE
LIXTE Biotechnology Attending the DealFlow Discovery Conference, January 28-29
IBN Initiates Coverage of LIXTE Biotechnology Holdings Inc.
Spartan Capital Securities, LLC Serves as Placement Agent in Lixte Biotechnology Holdings, Inc.'s $4.3 Million Registered Direct Offering
Lixte Biotechnology Holdings, Inc. Announces $4.3 Million Registered Direct Offering Priced at the Market Under Nasdaq Rules
LIXTE's Strategy Comes Into Focus: Building an Oncology Platform Around Complementary Modalities
LIXTE Levels Up From PP2A Innovation to Multi-Modal Oncology
LIXTE Steps Into a Key Role in the Rise of Treatment Amplifiers

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.